Heme/Onc

Avastin and the Meaning of Evidence

September 9, 2011
Avastin and the Meaning of Evidence

By Antonella Surbone MD PhD and Jerome Lowenstein MD

The recent hearings at the Food and Drug Administration regarding the revocation of approval for the use of Avastin in the treatment of breast cancer bring into sharp focus several very important issues in medicine today.

The pharmaceutical industry, armed with powerful new tools for deciphering the signaling mechanisms and mutations responsible for the development and progression of malignancies, has developed new therapies for treating cancer and other malignancies. The cost of development of each …

Read more »

Should My Patient with a Solid Tumor be Anticoagulated in the Absence of Venous Thromboembolism?

September 8, 2011
Should My Patient with a Solid Tumor be Anticoagulated in the Absence of Venous Thromboembolism?

By David Altszuler, Class of 2012

Faculty Peer Reviewed

An empiric association between occult malignancy and thrombophlebitis has been recognized since Trousseau first reported the syndrome in 1865.  The mechanism by which cancer predisposes to thrombophilia has not been fully elucidated; however, it is now clear that this is a symbiotic relationship.  The second leading cause of death in hospitalized cancer patients (and a leading cause of death in ambulatory cancer patients) is venous thromboembolism.  There are algorithms to identify cancer patients at high risk …

Read more »

Low Dose Vitamin K Supplementation and Anticoagulation Control

July 21, 2011
Low Dose Vitamin K Supplementation and Anticoagulation Control

By Joanna Becker

Faculty Peer Reviewed

Patients who are placed on long-term warfarin (Coumadin) therapy are sent home with a lengthy list of restrictions to minimize variations in warfarin efficacy. The agents that can alter warfarin levels can be divided into 2 categories: (1) those that interact with cytochrome P450, which metabolizes warfarin and (2) those that alter phytonadione (vitamin K) levels.  The majority of inter- and intra-individual warfarin dose variability is attributable to the agents in category 1 above, which include everything from antibiotics, …

Read more »

From The Archives: Myths and Realities: Do Power Lines Cause Cancer?

April 14, 2011
From The Archives: Myths and Realities: Do Power Lines Cause Cancer?

Please enjoy this post from the Clinical Correlations archives first posted May 20, 2009

By Aditya Mattoo, MD

Faculty Peer Reviewed

Prompted by personal experience, I thought I would explore the alleged causative role of power lines in hematologic malignancies for the next installment of Myths and Realities. In recent years, two close family friends living at separate locations but in homes adjacent to lots with electrical transformers were diagnosed with Multiple Myeloma and Non-Hodgkin’s Lymphoma. Naturally, the coincidence was not unnoticed, so I decided …

Read more »

From The Archives: The Skinny on Cachexia…Can it be Treated?

March 24, 2011
From The Archives: The Skinny on Cachexia…Can it be Treated?

Please enjoy this post from the Clinical Correlations archives first posted April 22, 2009

Michael T. Tees, MD, MPH

On the wards and in the clinic, the physician is frequently presented with a patient with a decreased appetite and alarming weight loss. The patient is likely frustrated with their own fraility, the family is upset at the poor nutritional state of their loved one, but the healthcare provider should be the most concerned. This clinical presentation without a prior diagnosis is worrisome, and if the …

Read more »

Medicine by the Numbers: Blood Count

March 4, 2011
Medicine by the Numbers: Blood Count

By Michael Ford, MD

Faculty Peer Reviewed

  

                                             

2.65 x 10 # of erythrocytes in circulation, assuming Hematocrit 45%         120 Lifespan in days of an erythrocyte         2.5 million # of new erythrocytes produced each second to replace dying cells†         5.3 million # of erythrocytes per microliter of blood†,*         4,000 – 11,000 # leukocytes per microliter of blood         150,000 – 400,000 # platelets per microliter of blood         15.9 Grams of Hemoglobin A per deciliter of blood†         64,400 Molecular mass in grams of Hemoglobin A (protein tetramer)        …

Read more »

Erythrocyte Index

February 10, 2011
Erythrocyte Index

By Michael Ford, MD

Faculty Peer Reviewed

“Blood Count”

2.65 x 10 # of erythrocytes in circulation, assuming Hematocrit 45% 120 Lifespan in days of an erythrocyte 2.5 million # of new erythrocytes produced each second to replace dying cells† 5.3 million # of erythrocytes per microliter of blood†,* 4,000 – 11,000 # leukocytes per microliter of blood 150,000 – 400,000 # platelets per microliter of blood 15.9 Grams of Hemoglobin A per deciliter of blood† 64,400 Molecular mass in grams of Hemoglobin A (protein…

Read more »

Medicine By Numbers

January 21, 2011
Medicine By Numbers

How to Counsel a Patient on Prostate Cancer Screening in 5 Minutes

By Caprice Cadacio, MD

Faculty Peer Reviewed

A good screening test is relatively inexpensive and noninvasive.  In addition, effective treatment should be available if the disease  being screened for is confirmed.  Lastly, detecting the disease before a patient becomes symptomatic must be more beneficial than detection after the patient experiences signs or symptoms.

The latter point is often debated in prostate cancer screening, which is done by obtaining a serum prostate specific antigen …

Read more »